18:20 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Ascentage hops in Hong Kong IPO queue

Ascentage Pharma Group International (Suzhou, China) proposed Aug. 20 to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by BofA Merrill Lynch and Citi. The biotech's pipeline comprises seven clinical...
19:47 , Aug 20, 2018 |  BC Extra  |  Financial News

Ascentage hops in Hong Kong IPO queue

Ascentage Pharma Group International (Suzhou, China) proposed Monday to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by BofA Merrill Lynch and Citi. The biotech's pipeline comprises seven clinical candidates...
23:33 , Oct 23, 2017 |  BC Extra  |  Preclinical News

Researchers identify new targets for DMD

Two studies published in Nature Communications show that decreasing expression of nuclear factor I X (NFIX) or sarcolipin (SLN) improves phenotypes associated with Duchenne muscular dystrophy in mouse models of the disease, identifying new targets...
01:46 , Dec 2, 2015 |  BC Extra  |  Company News

Management tracks

Opthalmology company Avalanche Biotechnologies Inc. (NASDAQ:AAVL) hired Paul Cleveland as CEO, effective Dec. 9. Cleveland was CEO at Celladon Corp. (NASDAQ:CLDN). Oncology and inflammation play Zai Laboratory Ltd. (Shanghai, China) named Qi Liu CMO. Liu...
01:56 , Nov 20, 2015 |  BC Extra  |  Company News

Eiger reverse-merges with Celladon

Eiger Biopharmaceuticals Inc. (San Carlos, Calif.) will acquire Celladon Corp. (NASDAQ:CLDN) through a reverse merger. Eiger President and CEO David Cory will lead the combined company, which will be named Eiger and will trade on...
07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Event planner

For investors who are not inclined to sit it out until the volatility abates, the fourth quarter is bursting with late-stage catalysts. There are no fewer than 17 PDUFA dates on the calendar before year...
07:00 , Jul 27, 2015 |  BioCentury  |  Strategy

Rules of competition

Competing in gene therapy is unlikely to follow the same rules as competing in other therapeutic categories where - even in Orphan diseases - a better product can steal market share. The reason is that...
07:00 , Jul 23, 2015 |  BC Innovations  |  Tools & Techniques

Gene therapy's coming of age

After more than 20 years of trial and error in gene therapy, the field is taking off with one product approved in Europe, several poised to enter the market in the U.S., a surge of...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Company News

Celladon cardiovascular news

Celladon will discontinue R&D and will cut the remainder of its R&D staff, or about 50% of its remaining 17 employees, after its board unanimously agreed to seek a sale of the company or its...
07:00 , Jul 13, 2015 |  BioCentury  |  Finance

Big news

The performance of big cap biotechs has lagged that of companies one tier down, but the second half includes a host of milestones that could put the bellwethers on a steeper upward trajectory. Buysiders largely...